Desk›Healthcare› Oxygenta Pharmaceutical Ltd
Oxygenta Pharmaceutical Ltd
BSE 524636 · NSE OXYGENTAPH · ISIN INE102E01018 · Group XT · Active
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
₹59.48
-1.46%
BSE close, 28 August 2026
₹219.98 cr
3.7 cr shares · Micro cap
₹95.60 cr
as published
-16.2× · -10.40×
EPS ₹-3.67 · BV ₹-5.72
112.98 / -17.57
₹ cr, as filed
13
3 selected · 23%
Reg 30
Sch. III Part A
Price 52-week, BSE
| Against 52-week high | -24.6% |
|---|---|
| Against 52-week low | +38.3% |
| Day change | -1.46% |
| Size band | Micro cap |
| Index membership | None |
Valuation as published by BSE
| Earnings per share | ₹-3.67 |
|---|---|
| Price / earnings | -16.21× |
| Price / book | -10.40× |
| Book value — derived, price ÷ P/B | ₹-5.72 |
| Return on equity | 64.24% |
| Operating margin | 1.54% |
| Net margin | -5.69% |
Consistency check
- P/B ÷ P/E, which must equal ROE
- 64.16%
- ROE as published
- 64.24%
Results ₹ crore, as filed
RevenueNet profit one scale across all three periods, ₹ crore
| Period | Revenue ₹cr | Net profit ₹cr | EPS ₹ | OPM | NPM |
|---|---|---|---|---|---|
| Jun-26 · Q | 37.00 | -2.10 | -0.57 | 1.54% | -5.69% |
| Mar-26 · Q | 49.61 | -1.70 | -0.45 | 0.58% | -3.43% |
| FY25-26 | 112.98 | -17.57 | -4.75 | -13.35% | -15.55% |
Quarter on quarter
- Revenue, quarter on quarter
- -25.4%
- Net profit, quarter on quarter
- -23.5%
- Operating margin, quarter on quarter
- +96 bps
Disclosure profile 13 filings in the window
| Tag | Filings |
|---|---|
| Selected | |
| Board Outcome | 1 |
| Change in Management | 1 |
| Results | 1 |
| Selected sub-total | 3 |
| Procedural | |
| AGM / EGM | 4 |
| Board Meeting | 2 |
| General | 2 |
| Annual Report | 1 |
| Trading Window | 1 |
| Procedural sub-total | 10 |
| Total | 13 |
Disclosure regime
LODR Reg 30
Read with Schedule III Part A. An equity filer in BSE Group XT, so the Regulation 30 disclosure framework and the Schedule III event list both apply.
Filing rhythm · 93 trading days
13 filings · 3 selected · busiest 2026-07-27 and 2026-07-30
Filing rhythm · the twelve most recent
2026-07-242026-10-01
SelectedProcedural
Filings
13 in the window · 2 earlier on record
-
1 October 2026 ·
Announcement Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015-Purchase Of Land
Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015.
Company Update / General View filing →
-
29 September 2026 ·
Closure of Trading Window
Closure of trading window for the period ending on 30th September, 2026.
Insider Trading / SAST / Closure of Trading Window View filing →
-
21 August 2026 ·
Shareholder Meeting / Postal Ballot-Scrutinizer's Report
Disclosure under Regulation 44(3) of SEBI (LODR), Regulations, 2015.
AGM/EGM / AGM View filing →
-
21 August 2026 ·
Shareholder Meeting / Postal Ballot-Outcome of AGM
Outcome of 33rd Annual General Meeting held on 21.08.2026.
AGM/EGM / AGM View filing →
-
31 July 2026 ·
Newspaper Advertisement
Newspaper Advertisement for Notice of AGM scheduled to be held on 21st August, 2026.
Company Update / General View filing →
-
30 July 2026 ·
Intimation Of Book Closure And Cut-Off Date For The 33Rd Annual General Meeting Of Oxygenta Pharmaceutical Limited.
Intimation of Book Closure and Cut-off Date for the AGM
AGM/EGM / AGM View filing →
-
30 July 2026 ·
Reg. 34 (1) Annual Report.
Submission of 33rd Annual Report for the Financial Year 2025-26 under Regulation 34 of SEBI (LODR), Regulations, 2015
Others / Reg. 34 (1) Annual Report View filing →
-
30 July 2026 ·
Submission Of Notice Of 33Rd Annual General Meeting For The Finanical Year 2025-26.
Notice of 33rd Annual General Meeting for the Financial Year 2025-26.
AGM/EGM / AGM View filing →
-
27 July 2026 ·
Change in Management
Appointment of Cost Auditor for the Financial Year 2026-27.
Company Update / Change in Management View filing →
-
27 July 2026 ·
Un-Audited Results For The Quarter Ended 30.06.2026.
Un-audited Financial Results for the Quarter ended 30.06.2026.
Result / Financial Results View filing →
-
27 July 2026 ·
Board Meeting Outcome for Outcome For The Board Meeting Held On 27.07.2026
Un-audited Financial results for the Quarter ended 30.06.2026.
Board Meeting / Outcome of Board Meeting View filing →
-
24 July 2026 ·
Update on board meeting
The Board Meeting to be held on 25/07/2026 has been revised to 27/07/2026 Postponement of the Board Meeting to be held on Saturday, 25th July, 2026 and rescheduling of the board meeting ....
Company Update / Board Meeting Rescheduled View filing →
-
22 July 2026 ·
Board Meeting Intimation for The Meeting To Be Held On Saturday, 25Th Day Of July, 2026
Oxygenta Pharmaceutical Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/07/2026 ,inter alia, to consider and approve 1. Unaudited Financial ....
Board Meeting / Board Meeting View filing →
RSS feed for Oxygenta Pharmaceutical Ltd · the 50 most recent filings